急性GVHD预防联合ATLG在HLA全合同胞清髓性异基因外周血干细胞移植后缓解期急性髓系白血病患者中的3期随机研究:生活质量和长期结局分析的最终结果
该3期随机研究报告,在HLA全合同胞清髓性外周血干细胞移植的缓解期急性白血病患者中,ATLG联合标准GVHD预防较单用标准预防显著降低2年cGVHD发生率和严重度,并改善cGRFS。长期随访(中位5.9年)证实ATLG组5年cGVHD发生率更低、cGRFS更高、免疫抑制治疗患者更少,且不增加复发;生活质量在多维度上更优。
要点
- ATLG组5年cGVHD累积发生率30.0% vs 非ATLG组69.1%,整个随访期分析p<0.001。
- ATLG组5年cGRFS 34.3% vs 非ATLG组13.9%,p=0.005;复发率两组无显著差异(p=0.09)。
- ATLG组仍在使用免疫抑制治疗的患者比例9.6% vs 非ATLG组28.3%,p=0.017。
核心结论
- 在HLA全合同胞清髓性外周血干细胞移植的缓解期急性白血病患者中,ATLG联合标准GVHD预防较单用标准GVHD预防改善无病无cGVHD生存概率。
- ATLG组较非ATLG组生活质量更优且免疫抑制治疗时间更短。
- 作者认为在此背景下,ATLG联合标准GVHD预防应优先于单用标准GVHD预防。
研究设计与样本
- 原始研究为开放标签3期随机研究,纳入首次或后续缓解的急性髓系和急性淋巴细胞白血病患者,接受HLA全合同胞异基因外周血干细胞移植,按1:1随机分配至ATLG联合环孢素和短程甲氨蝶呤组(ATLG组)或不含ATLG的标准GVHD预防组(非ATLG组),随机化按中心和疾病风险分层。
- 预处理方案为环磷酰胺120 mg/kg联合全身照射(12 Gy)或白消安(静脉12.8 mg/kg或口服16 mg/kg),联合或不联合依托泊苷(30-60 mg/kg)。
- 原始研究主要终点为2年cGVHD累积发生率;生活质量(QoL)为未发表的次要终点,使用欧洲癌症研究与治疗组织QLQ-C30和QLQ-HDC29问卷评估。
- 随访扩展研究主要终点为cGVHD累积发生率;原始研究(NCT00678275)和随访扩展研究(NCT03042676)均已注册。
- 原始研究于2006年12月14日至2012年2月2日入组161例患者,155例随机分配至ATLG组(n=83)或非ATLG组(n=72);随访研究于2017年2月7日开始、2017年6月30日完成,纳入ATLG组61例、非ATLG组53例。
主要发现
- 整体健康状况在ATLG组较非ATLG组呈现更有利的时间进程(p=0.02;治疗与访视交互作用)。
- 24个月时ATLG组在躯体功能(点估计-14.8 [95% CI -26.4至-3.1];p=0.014)、社会功能(-19.1 [-38.0至-0.2];p=0.047)、胃肠道副作用(8.8 [2.5-15.1];p=0.008)和对家庭的影响(13.5 [1.2-25.8];p=0.032)方面描述性优于非ATLG组。
- 扩展随访(中位5.9年 [IQR 1.7-7.9])显示ATLG组较非ATLG组5年cGVHD发生率更低(30.0% [95% CI 21.4-41.9] vs 69.1% [59.1-80.1];整个随访期分析p<0.001)。
- ATLG组较非ATLG组复发率无显著增加(35.4% [26.4-47.5] vs 22.5% [14.6-34.7];p=0.09),cGRFS改善(34.3% [24.2-44.5] vs 13.9% [7.1-22.9];p=0.005),仍在免疫抑制治疗的患者更少(9.6% vs 28.3%;p=0.017)。
- 5年总生存、无复发生存和非复发死亡率在两组间无显著差异。
关键数值与推荐
- ATLG组5年cGVHD累积发生率为30.0% [95% CI 21.4-41.9],非ATLG组为69.1% [59.1-80.1];整个随访期分析p<0.001。
- ATLG组5年cGRFS为34.3% [95% CI 24.2-44.5],非ATLG组为13.9% [7.1-22.9];p=0.005。
- ATLG组5年复发率为35.4% [95% CI 26.4-47.5],非ATLG组为22.5% [14.6-34.7];p=0.09。
- ATLG组仍在使用免疫抑制治疗的患者比例为9.6%,非ATLG组为28.3%;p=0.017。
- 24个月时ATLG组较非ATLG组躯体功能点估计为-14.8 [95% CI -26.4至-3.1];p=0.014。
临床怎么用
- 作者认为在此背景下,ATLG联合标准GVHD预防应优先于单用标准GVHD预防。
- ATLG联合标准GVHD预防较单用标准GVHD预防可改善无病无cGVHD生存概率、生活质量,并缩短免疫抑制治疗时间。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously showed that human anti-T-lymphocyte globulin (ATLG) plus ciclosporin and methotrexate given to patients with acute leukaemia in remission, having allogeneic haemopoietic stem-cell transplantation with peripheral blood stem cells from an HLA-identical sibling donor after myeloablative conditioning, significantly reduced 2-year chronic graft-versus-host disease (cGVHD) incidence and severity, without increasing disease relapse and infections, and improves cGVHD-free and relapse-free survival (cGRFS). The aim of an extended follow-up study was the assessment of long-term outcomes, which are, in this context, scarcely reported in the literature. We report unpublished data on quality of life (QoL) from the original study and the results of a follow-up extension. METHODS: In the original open-label study, patients with acute myeloid and lymphoblastic leukaemia in first or subsequent remission, having sibling HLA-identical allogeneic peripheral blood stem-cell transplantation, were randomly assigned (1:1) to receive ATLG plus standard GVHD prophylaxis with ciclosporin and short-term methotrexate (ATLG group) or standard GVHD prophylaxis without ATLG (non-ATLG group). Conditioning regimens were cyclophosphamide 120 mg/kg with either total body irradiation (12 Gy) or busulfan (12·8 mg/kg intravenously or 16 mg/kg orally), with or without etoposide (30-60 mg/kg). Randomisation was stratified according to centre and disease risk. The primary endpoint was cumulative incidence of cGVHD at 2 years. The primary and secondary endpoints, excluding QoL, have been published. QoL, assessed using European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-HDC29 questionnaires, was an unpublished secondary endpoint, which we now report here. A follow-up extension was then done, with the primary endpoint cumulative incidence of cGVHD. Enrolment has been completed for both studies. The original trial (number, NCT00678275) and follow-up extension (number, NCT03042676) are registered at ClinicalTrials.gov. FINDINGS: In the original study, from Dec 14, 2006, to Feb 2, 2012, 161 patients were enrolled and 155 were randomly assigned to either the ATLG group (n=83) or to the non-ATLG group (n=72). In the follow-up study, which started on Feb 7, 2017, and was completed on June 30, 2017, 61 patients were included in the ATLG group and 53 were included in the non-ATLG group. Global health status showed a more favourable time course in the ATLG group compared with the non-ATLG group (p=0·02; treatment by visit interaction). ATLG was descriptively superior to non-ATLG at 24 months for physical function (points estimate -14·8 [95% CI -26·4 to -3·1]; p=0·014) and social function (-19·1 [-38·0 to -0·2]; p=0·047), gastrointestinal side-effects (8·8 [2·5-15·1]; p=0·008) and effect on family (13·5 [1·2-25·8]; p=0·032). Extended follow-up (median 5·9 years [IQR 1·7-7·9]) confirmed a lower 5-year cGVHD incidence (30·0% [95% CI 21·4-41·9] vs 69·1% [59·1-80·1]; analysis for entire follow-up, p<0·001), no increase in relapses (35·4% [26·4-47·5] vs 22·5% [14·6-34·7]; p=0·09), improved cGRFS (34·3% [24·2-44·5] vs 13·9% [7·1-22·9]; p=0·005), and fewer patients still in immunosuppression (9·6% vs 28·3%; p=0·017) in the ATLG group compared with the non-ATLG group. 5-year overall survival, relapse-free survival, and non-relapse mortality did not differ significantly between groups. INTERPRETATION: The addition of ATLG to standard GVHD prophylaxis improves the probability of surviving without disease relapse and cGVHD after myeloablative peripheral blood stem-cell transplantation from an HLA-identical sibling donor for patients with acute leukaemia in remission. Further additional benefits are better QoL and shorter immunosuppressive treatment compared with standard GVHD prophylaxis without ATLG. Therefore, in this setting, ATLG plus standard GVHD prophylaxis should be preferred over the standard GVHD prophylaxis alone. FUNDING: Neovii Biotech.
引用
- Bonifazi F, Solano C, Wolschke C, et al. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. Lancet Haematol. 2019. PMID: 30709437. doi:10.1016/S2352-3026(18)30214-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。